CYTH - Cyclo Therapeutics secures $12M capital through equity raise
Cyclo Therapeutics (NASDAQ:CYTH) has priced its public offering of 1.95M shares of common stock at $6.00/share, for expected gross proceeds of $11.7M. Underwriter's over-allotment is an additional 292.5K shares. Maxim Group is acting as sole book-running manager. Earlier, CYTH stock gained after filing IND application for Trappsol Cyclo in Alzheimer’s Disease. Shares down 13.4% after-hours with last close of $7.34. Previously (Nov. 16): Cyclo Therapeutics under pressure on launching stock offering
For further details see:
Cyclo Therapeutics secures $12M capital through equity raise